| International staging system for multiple myeloma PR Greipp, JS Miguel, BGM Durie, JJ Crowley, B Barlogie, J Bladé, ... Journal of clinical oncology 23 (15), 3412-3420, 2005 | 3704 | 2005 |
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, ... New England journal of medicine 352 (24), 2487-2498, 2005 | 3086 | 2005 |
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group International Myeloma Working Group British journal of haematology 121 (5), 749-757, 2003 | 2616 | 2003 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2476 | 2016 |
| Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial A Palumbo, S Bringhen, T Caravita, E Merla, V Capparella, V Callea, ... The Lancet 367 (9513), 825-831, 2006 | 1051 | 2006 |
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ... Leukemia 23 (2), 215-224, 2009 | 1035 | 2009 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1022 | 2008 |
| Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and … RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ... Leukemia 24 (6), 1121-1127, 2010 | 1016 | 2010 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| Autologous transplantation and maintenance therapy in multiple myeloma A Palumbo, F Cavallo, F Gay, F Di Raimondo, D Ben Yehuda, MT Petrucci, ... New England Journal of Medicine 371 (10), 895-905, 2014 | 894 | 2014 |
| MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis F Pichiorri, SS Suh, M Ladetto, M Kuehl, T Palumbo, D Drandi, C Taccioli, ... Proceedings of the National Academy of Sciences 105 (35), 12885-12890, 2008 | 735 | 2008 |
| Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, ... Blood, The Journal of the American Society of Hematology 110 (10), 3557-3560, 2007 | 683 | 2007 |
| A comparison of allografting with autografting for newly diagnosed myeloma B Bruno, M Rotta, F Patriarca, N Mordini, B Allione, F Carnevale-Schianca, ... New England Journal of Medicine 356 (11), 1110-1120, 2007 | 656 | 2007 |
| Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation BGM Durie, RA Kyle, A Belch, W Bensinger, J Blade, M Boccadoro, ... The Hematology Journal 4 (6), 379-398, 2003 | 621 | 2003 |
| Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up MA Dimopoulos, P Moreau, E Terpos, MV Mateos, S Zweegman, G Cook, ... Hemasphere 5 (2), e528, 2021 | 585 | 2021 |
| Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J San Miguel, ... Blood, The Journal of the American Society of Hematology 117 (18), 4701-4705, 2011 | 533 | 2011 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria, M Offidani, ... Journal of Clinical Oncology 28 (34), 5101-5109, 2010 | 520 | 2010 |
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients S Bringhen, A Larocca, D Rossi, M Cavalli, M Genuardi, R Ria, S Gentili, ... Blood, The Journal of the American Society of Hematology 116 (23), 4745-4753, 2010 | 497 | 2010 |
| Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) A Palumbo, S Bringhen, H Ludwig, MA Dimopoulos, J Bladé, MV Mateos, ... Blood, The Journal of the American Society of Hematology 118 (17), 4519-4529, 2011 | 464 | 2011 |
| Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial A Palumbo, S Bringhen, AM Liberati, T Caravita, A Falcone, V Callea, ... Blood, The Journal of the American Society of Hematology 112 (8), 3107-3114, 2008 | 455 | 2008 |
